EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Measuring repeatability of dynamic contrast-enhanced MRI biomarkers improves evaluation of biological response to radiotherapy in lung cancer

Nivetha Sridharan, Ahmed Salem, Ross A Little, Maira Tariq, Susan Cheung, Michael J Dubec, Corinne Faivre-Finn, Geoffrey J M Parker, Nuria Porta, James P B O'Connor

European Radiology · 2024

DOI: 10.1007/s00330-024-10970-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Radiology, 2024. Verfasst von Nivetha Sridharan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. nivetha.sridharan@icr.ac.uk. Hauptthemen laut MEDLINE: Lung Neoplasms, Magnetic Resonance Imaging, Contrast Media, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To measure dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) biomarker repeatability in patients with non-small cell lung cancer (NSCLC). To use these statistics to identify which individual target lesions show early biological response. Materials and methods A single-centre, prospective DCE-MRI study was performed between September 2015 and April 2017. Patients with NSCLC were scanned before standard-of-care radiotherapy to evaluate biomarker repeatability and two weeks into therapy to evaluate biological response. Volume transfer constant ( K trans ), extravascular extracellular space volume fraction ( v e ) and plasma volume fraction ( v p ) were measured at each timepoint along with tumour volume. Repeatability was assessed using a within-subject coefficient of variation (wCV) and repeatability coefficient (RC). Cohort treatment effects on biomarkers were estimated using mixed-effects models. RC limits of agreement revealed which individual target lesions changed beyond that expected with biomarker daily variation.

Results

Fourteen patients (mean age, 67 years +/− 12, 8 men) had 22 evaluable lesions (12 primary tumours, 8 nodal metastases, 2 distant metastases). The wCV (in 8/14 patients) was between 9.16% to 17.02% for all biomarkers except for v p , which was 42.44%. Cohort-level changes were significant for K trans and v e ( p < 0.001) and tumour volume ( p = 0.002). K trans and tumour volume consistently showed the greatest number of individual lesions showing biological response. In distinction, no individual lesions had a real change in v e despite the cohort-level change.

Conclusion

Identifying individual early biological responders provided additional information to that derived from conventional cohort cohort-level statistics, helping to prioritise which parameters would be best taken forward into future studies. Clinical relevance statement Dynamic contrast-enhanced magnetic resonance imaging biomarkers K trans and tumour volume are repeatable and detect early treatment-induced changes at both cohort and individual lesion levels, supporting their use in further evaluation of radiotherapy and targeted therapeutics. Key Points Few literature studies report quantitative imaging biomarker precision, by measuring repeatability or reproducibility . Several DCE-MRI biomarkers of lung cancer tumour microenvironment were highly repeatable . Repeatability coefficient measurements enabled lesion-specific evaluation of early biological response to therapy, improving conventional assessment .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsMagnetic Resonance ImagingContrast MediaCarcinoma, Non-Small-Cell LungHumansMaleFemaleAgedProspective StudiesReproducibility of ResultsMiddle AgedTreatment OutcomeBiomarkers, Tumor

Stichwörter der Autor:innen

BiomarkersLung neoplasmsMagnetic resonance imagingStatistics

Substanzen

Contrast MediaBiomarkers, Tumor

Autor:innen und Institutionen

  • Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. nivetha.sridharan@icr.ac.uk.
  • Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK. nivetha.sridharan@icr.ac.uk.
  • Division of Cancer Sciences, University of Manchester, Manchester, UK.
  • Department of Anatomy, Physiology and Biochemistry, Faculty of Medicine, The Hashemite University, Zarqa, Jordan.
  • Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
  • Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK.

Förderung

  • Cancer Research UK

Zitieren

APA

Sridharan, N., Salem, A., Little, R. A., Tariq, M., Cheung, S., Dubec, M. J., Faivre-Finn, C., Parker, G. J. M., Porta, N., & O'Connor, J. P. B. (2024). Measuring repeatability of dynamic contrast-enhanced MRI biomarkers improves evaluation of biological response to radiotherapy in lung cancer. European Radiology. https://doi.org/10.1007/s00330-024-10970-7

Vancouver

Sridharan N, Salem A, Little RA, Tariq M, Cheung S, Dubec MJ, et al. Measuring repeatability of dynamic contrast-enhanced MRI biomarkers improves evaluation of biological response to radiotherapy in lung cancer. European Radiology. 2024. doi:10.1007/s00330-024-10970-7

BibTeX
@article{Sridharan2024,
  author = {Sridharan, Nivetha and Salem, Ahmed and Little, Ross A and Tariq, Maira and Cheung, Susan and Dubec, Michael J and Faivre-Finn, Corinne and Parker, Geoffrey J M and Porta, Nuria and O'Connor, James P B},
  title = {Measuring repeatability of dynamic contrast-enhanced MRI biomarkers improves evaluation of biological response to radiotherapy in lung cancer},
  journal = {European Radiology},
  year = {2024},
  doi = {10.1007/s00330-024-10970-7}
}
Kostenlos starten →